Controlled substances; psychoactive derivatives of hemp added as Schedule I drug
SB132 revises Alabama’s controlled substances law to narrow the hemp exemption for tetrahydrocannabinols. Under current law, THC found in hemp is exempt from Schedule I; this bill would limit that exemption to non-psychoactive cannabinoids derived from or found in hemp, which would have the effect of classifying psychoactive hemp-derived cannabinoids such as delta-8 THC, delta-9 THC, and delta-10 THC as Schedule I controlled substances. The bill also makes conforming changes to the state’s Schedule I list and related synthetic controlled substance provisions.
In addition to the hemp/THC change, the bill repeals Section 13A-12-214.4, which currently prohibits the sale of psychoactive cannabinoids to minors. The bill’s effective date would be October 1, 2025. As drafted, it would significantly expand the reach of Alabama drug-control law over hemp-derived intoxicating products and remove the separate statutory age-based sales restriction, replacing it with a broader controlled-substance classification.
The bill’s impact would be felt by hemp retailers, manufacturers, distributors, and consumers of psychoactive cannabinoid products, especially products marketed as alternatives to marijuana. It would also affect law enforcement and forensic testing agencies by requiring these substances to be treated as Schedule I controlled substances rather than regulated hemp products. The bill’s caption and text indicate a policy shift toward treating intoxicating hemp derivatives more like illegal drugs than consumer hemp products.
There is no recorded committee transcript, vote history, or floor debate in the provided materials, so the public sentiment cannot be measured from discussion or roll calls. Based on the bill’s structure and caption, the measure appears to reflect a restrictive approach to psychoactive hemp products, but the available record does not show direct support or opposition from legislators in committee. The absence of votes or transcripts also means no specific stakeholder objections are documented here.
The main point of contention inherent in the bill is the treatment of psychoactive hemp cannabinoids: supporters would likely view the bill as a public-safety and drug-control measure, while opponents would likely argue it sweeps in legal hemp-derived products and disrupts an emerging market. Another possible issue is the repeal of the existing minor-sales restriction, since the bill replaces a targeted age limit with a broader criminal classification rather than preserving both approaches.
SB132 would amend Section 20-2-23 of the Code of Alabama 1975 to limit the hemp exemption in Schedule I to non-psychoactive cannabinoids and to treat psychoactive hemp-derived cannabinoids as controlled substances. It would also repeal Section 13A-12-214.4, eliminating the separate prohibition on selling psychoactive cannabinoids to minors. The bill would therefore change the legal status of delta-8, delta-9, delta-10, and similar intoxicating hemp products, affecting hemp businesses, consumers, law enforcement, and forensic/public health agencies.
No committee transcripts or votes were provided, so there is no documented debate or recorded sentiment from the legislative process in the materials supplied. The bill’s caption and text suggest a generally restrictive posture toward psychoactive hemp products, but the available record does not show whether that approach was broadly supported or opposed by members or stakeholders.
The central controversy is whether psychoactive hemp-derived cannabinoids should remain exempt as hemp products or be treated as Schedule I controlled substances. Supporters of the bill would likely emphasize public health, youth access, and the need to close a perceived loophole in hemp law; opponents would likely argue that the bill overcriminalizes products derived from hemp, harms lawful businesses, and blurs the line between intoxicating and non-intoxicating cannabinoids. A secondary point of concern is that the bill repeals the existing minor-sales restriction rather than retaining it alongside the broader scheduling change.